Danaher Corporation
Danaher Corporation designs, manufactures, and markets products globally. The Biotechnology segment offers bioprocess technologies and services for therapeutic development. The Life Sciences segment provides mass spectrometers, flow cytometry instruments, and genomic medicines. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems. Danaher also provides clinical instruments, reagents, consumables, software, and services for hospitals and laboratories. The company has a research collaboration with Stanford Universitys Department of Bioengineering for cancer drug development.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): an asset-light, cash-generative model, high, stable gross margins (pricing power) and operating margins that held up every year.
- Pricing power: gross margin has held between 56% and 61% over the last 6 years (latest 59.1%).
- Asset-light, cash-generative model: capital expenditure takes only 4.8% of revenue and free cash flow was positive in each of the last 6 years.
- Scale advantage: ranks #2 by enterprise value ($174 billion) among the 31 Diagnostics & Research companies we cover.
Weaknesses
- Our discounted cash flow target price (100.95 USD) is 55% below the current price.
- Valued at a premium to its Diagnostics & Research peers: P/E 44.3x vs. a median of 31.4x and EV/EBITDA 24.2x vs. a median of 15.5x.
Key Financial Data